IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4179 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed16940    
    Printed274    
    Emailed16    
    PDF Downloaded1260    
    Comments [Add]    

Recommend this journal

 

 REVIEW ARTICLE
Year : 2004  |  Volume : 70  |  Issue : 2  |  Page : 67--75

Therapeutic options for systemic sclerosis


Dept. of Rheumatology, Seth GS Medical College and KEM Hospital, Mumbai, India

Correspondence Address:
Lata S Bichile
Dept. of Rheumatology, Seth GS Medical College and KEM Hospital, Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17642568

Rights and PermissionsRights and Permissions

Systemic sclerosis is a uncommon connective tissue disorder characterized by vascular damage, immune cell activation and fibrogenesis. Each of these components may respond to different therapies. Therefore, a combination strategy treating all three processes is more likely to control the disease than single agent therapy. Clinical trials have gone a long way towards defining the therapy of scleroderma and many drugs previously used for scleroderma have been critically assessed. Angiotensin blockade is effective in treating as well as preventing scleroderma renal crisis. The 9-year cumulative survival has improved from 38% to 68% after the introduction of angiotensin blockade. There is definitive evidence supporting the use of cyclophosphamide in systemic sclerosis associated alveolitis. Newer molecules aimed at various cytokines are being tried. The therapy for systemic sclerosis is far from perfect at present. But, individualization of the treatment with respect to stage and subset of disease as well as organ involvement can eventually result in rational, effective management.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow